Drug Profile
Ciprofloxacin intratympanic - ALK-Abello
Alternative Names: AuriPro™; Ciprofloxacin otic suspension - Otonomy; OTIPRIO; OTO-201Latest Information Update: 04 Dec 2021
Price :
$50
*
At a glance
- Originator Otonomy
- Developer Otonomy; Otonomy [CEASED]
- Class Anti-infectives; Antibacterials; Carboxylic acids; Cyclopropanes; Fluoroquinolones; Piperazines; Small molecules
- Mechanism of Action DNA gyrase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Otitis externa; Otitis media
Most Recent Events
- 27 Sep 2021 No development reported - Phase-III for Otitis externa (In adolescents, In children, In the elderly, In infants, In adults) in Canada (Intratympanic)
- 27 Sep 2021 No development reported - Phase-III for Otitis media (In adolescents, In children, In infants) in Canada (Intratympanic)
- 03 Jun 2021 ALK Abello acquires Ciprofloxacin intratympanic from Otonomy